Philippe M. Maitre, Executive Vice President, US Operations discusses Onxeo and the company’s focus on orphan oncology products. Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the development of drugs for orphan oncology diseases, and Topotarget, a Danish biopharmaceutical company based in Copenhagen.
Onxeo develops innovative drugs for the treatment of orphan oncology diseases. The company is based in Paris and Copenhagen.